Literature DB >> 26419848

How to manage pasireotide, when using as medical treatment for Cushing's disease.

Stephan Petersenn1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26419848     DOI： 10.1007/s12020-015-0754-z

Source DB:  PubMed          Journal:  Endocrine        ISSN： 1355-008X            Impact factor:   3.633


× No keyword cloud information.
  18 in total

1.  Sustained improvements in plasma ACTH and clinical status in a patient with Nelson's syndrome treated with pasireotide LAR, a multireceptor somatostatin analog.

Authors:  Laurence Katznelson
Journal:  J Clin Endocrinol Metab       Date:  2013-03-28       Impact factor: 5.958

2.  Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly.

Authors:  Wouter W de Herder; H Rob Taal; Piet Uitterlinden; Richard A Feelders; Joop A M J L Janssen; Aart-Jan van der Lely
Journal:  Eur J Endocrinol       Date:  2005-07       Impact factor: 6.664

3.  Treatment effectiveness of pasireotide on health-related quality of life in patients with Cushing's disease.

Authors:  Susan M Webb; John E Ware; Anna Forsythe; Min Yang; Xavier Badia; Lauren M Nelson; James E Signorovitch; Lori McLeod; Mario Maldonado; Wojciech Zgliczynski; Christophe de Block; Lesly Portocarrero-Ortiz; Monica Gadelha
Journal:  Eur J Endocrinol       Date:  2014-04-23       Impact factor: 6.664

4.  A 12-month phase 3 study of pasireotide in Cushing's disease.

Authors:  Annamaria Colao; Stephan Petersenn; John Newell-Price; James W Findling; Feng Gu; Mario Maldonado; Ulrike Schoenherr; David Mills; Luiz Roberto Salgado; Beverly M K Biller
Journal:  N Engl J Med       Date:  2012-03-08       Impact factor: 91.245

5.  The European Registry on Cushing's syndrome: 2-year experience. Baseline demographic and clinical characteristics.

Authors:  Elena Valassi; Alicia Santos; Maria Yaneva; Miklós Tóth; Christian J Strasburger; Philippe Chanson; John A H Wass; Olivier Chabre; Marija Pfeifer; Richard A Feelders; Stylianos Tsagarakis; Peter J Trainer; Holger Franz; Kathrin Zopf; Sabina Zacharieva; Steven W J Lamberts; Antoine Tabarin; Susan M Webb
Journal:  Eur J Endocrinol       Date:  2011-06-29       Impact factor: 6.664

6.  The nadir growth hormone after an octreotide test dose predicts the long-term efficacy of somatostatin analogue therapy in acromegaly.

Authors:  J A Gilbert; J P Miell; S M Chambers; A M McGregor; S J B Aylwin
Journal:  Clin Endocrinol (Oxf)       Date:  2005-06       Impact factor: 3.478

7.  Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study.

Authors:  Astrid Breitschaft; Ke Hu; Karina Hermosillo Reséndiz; Christelle Darstein; Georg Golor
Journal:  Diabetes Res Clin Pract       Date:  2013-12-25       Impact factor: 5.602

8.  Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study.

Authors:  Rosario Pivonello; Stephan Petersenn; John Newell-Price; James W Findling; Feng Gu; Mario Maldonado; Andrew Trovato; Gareth Hughes; Luiz R Salgado; André Lacroix; Jochen Schopohl; Beverly M K Biller
Journal:  Clin Endocrinol (Oxf)       Date:  2014-03-27       Impact factor: 3.478

9.  Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing's disease: results from an open-ended, open-label extension trial.

Authors:  Jochen Schopohl; Feng Gu; Robert Rubens; Luc Van Gaal; Jérôme Bertherat; Monica Ligueros-Saylan; Andrew Trovato; Gareth Hughes; Luiz R Salgado; Marco Boscaro; Rosario Pivonello
Journal:  Pituitary       Date:  2015-10       Impact factor: 4.107

10.  Extended treatment of Cushing's disease with pasireotide: results from a 2-year, Phase II study.

Authors:  M Boscaro; J Bertherat; J Findling; M Fleseriu; A B Atkinson; S Petersenn; J Schopohl; P Snyder; G Hughes; A Trovato; K Hu; M Maldonado; B M K Biller
Journal:  Pituitary       Date:  2014-08       Impact factor: 4.107
View more
  4 in total

Review 1.  Diabetes in Cushing Disease.

Authors:  G Mazziotti; A M Formenti; S Frara; F Maffezzoni; M Doga; A Giustina
Journal:  Curr Diab Rep       Date:  2017-05       Impact factor: 4.810

2.  Long-term treatment of Cushing's disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial.

Authors:  S Petersenn; L R Salgado; J Schopohl; L Portocarrero-Ortiz; G Arnaldi; A Lacroix; C Scaroni; S Ravichandran; A Kandra; B M K Biller
Journal:  Endocrine       Date:  2017-06-09       Impact factor: 3.633

3.  Long-term efficacy and safety of once-monthly pasireotide in Cushing's disease: A Phase III extension study.

Authors:  Maria Fleseriu; Stephan Petersenn; Beverly M K Biller; Pinar Kadioglu; Christophe De Block; Guy T'Sjoen; Marie-Christine Vantyghem; Libuse Tauchmanova; Judi Wojna; Michael Roughton; André Lacroix; John Newell-Price
Journal:  Clin Endocrinol (Oxf)       Date:  2019-10-01       Impact factor: 3.478

4.  The treatment with pasireotide in Cushing's disease: effect of long-term treatment on clinical picture and metabolic profile and management of adverse events in the experience of a single center.

Authors:  C Simeoli; R Ferrigno; M C De Martino; D Iacuaniello; F Papa; D Angellotti; C Pivonello; R Patalano; M Negri; A Colao; R Pivonello
Journal:  J Endocrinol Invest       Date:  2019-07-16       Impact factor: 4.256
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.